Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (29)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  3. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  4. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  5. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

  6. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

2023

  1. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  2. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258

  3. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group

    Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10

2021

  1. Prevalence of nodal involvement in rectal cancer after chemoradiotherapy

    The British journal of surgery, Vol. 108, Núm. 10, pp. 1251-1258

2020

  1. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460

2019

  1. Clinical presentation, diagnosis and staging of cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 98-107

  2. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)

    Clinical and Translational Oncology

  3. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials

    Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471

2018

  1. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128

  2. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer

    Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629

  3. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)

    Cancer Chemotherapy and Pharmacology, Vol. 82, Núm. 6, pp. 935-943

  4. SEOM clinical guideline for treatment of kidney cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56

  5. The safety of ramucirumab for the treatment of colorectal cancer

    Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951